πŸ‡ΊπŸ‡Έ FDA
Patent

US 11807605

Human plasma kallikrein inhibitors

granted A61PA61P17/00A61P17/10

Quick answer

US patent 11807605 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61P, A61P17/00, A61P17/10, A61P7/00